Biostock publishes an article about the key milestone toward commercialisation – assay design freeze
Biostock publishes an article about Prolight Diagnostics has reached high-sensitivity troponin assay design freeze, locking in the final chemical configuration and performance characteristics. This marks a transition from the development phase to manufacturing optimization, setting the stage for the upcoming clinical performance study. Read the full article here: https://biostock.se/en/2025/12/prolight-diagnostics-nar-assay-design-freeze-for-det-hogkansliga-troponintestet-en-avgorande-milstolpe-for-psyros/ For further information, please contact:Ulf Bladin, […]
Prolight Diagnostics achieves assay design freeze for Psyros™ point-of-care cartridge – A key milestone toward commercialisation
Prolight Diagnostics today announced it has reached assay design freeze for its Psyros™ point-of-care cartridge, marking a major development milestone for the Psyros platform and an important step toward commercialisation. The design freeze confirms the final assay configuration and performance characteristics, freezing the cartridge chemistry. With this milestone achieved, Prolight can now transition to the […]
Prolight secures third patent in Europe for Psyros™
Prolight Diagnostics announces today that its third European patent for the Psyros single-molecule-counting technology has been granted in Europe by the European Patent Office (EPO), bringing the total number of patents granted in 2025 to three for the Psyros technology. The third patent is valid until 2042. “We are delighted that the EPO have granted another patent […]
BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study
BioStock publishes an article describing how Prolight Diagnostics is preparing the clinical study that will form the basis for the launch of the company’s high-sensitivity point of care troponin assay. Read the full article here: https://biostock.se/en/2025/12/prolights-cto-satter-fokus-pa-cro-partnern-mdx/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB […]
THE NOMINATION COMMITTEE APPOINTED FOR THE ANNUAL GENERAL MEETING 2026
The nomination committee is appointed in consultation with the three largest shareholders or owner groups, according to the number of votes based on shareholder statistics from Euroclear Sweden, and other reliable owner information in accordance with the decision of the Annual General Meeting. The nomination committee’s task is to produce proposals for the AGM regarding the […]
Prolight announces timetable for share reverse split
The extraordinary general meeting in Prolight Diagnostics AB (publ) on 19 November 2025, resolved on a reverse share split of 1:100, whereby one hundred (100) existing shares will be consolidated into one (1) new share. The extraordinary general meeting authorised the board of directors to determine the record date for the reverse share split. The […]
Prolight Diagnostics publishes quarterly report Q3, 2025
Financial overviewThird quarter, July 1 – September 30, 2025(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 577 (3,730) TSEK. Operating profit (EBIT) amounted to -13,908 (-8,731) TSEK. Profit after tax amounted to -13,909 (-8,795) TSEK. Earnings per share before and […]
Extraordinary general meeting of Prolight Diagnostics AB (publ) on 19 November 2025
The extraordinary general meeting (EGM) of Prolight Diagnostics AB (publ) took place on 19 November 2025 in Stockholm. The EGM resolved in accordance with the proposals by the board of directors. The main content of the main resolutions is described below. Resolution on (a) directed issue of shares (equalization issue), (b) amendment of the articles […]
BioStock publishes article about Prolight Diagnostics continued preparations to bring the Psyros platform to market
Read the full article here: https://biostock.se/en/2025/11/slutjusteringar-och-validering-i-fokus-hos-prolight-diagnostics-2/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems […]
Prolight Diagnostics publishes investor letter for November 2025
The investor letter notes, among other things that Prolight takes clear steps toward commercialization of the Psyros™ POC system. The investor letter is available via the attached file or on the company’s website: https://prolightdx.com/en/mediaeng/investor-letters/ For further information, please contact:Ulf Bladin, CEOE-mail: info@prolightdx.comPhone: +46 73 582 39 87Company website: www.prolightdx.com About UsProlight Diagnostics AB develops innovative […]